POPULARITY
21 episodes with GFR
25 episodes with GFR
7 episodes with GFR
7 episodes with GFR
8 episodes with GFR
5 episodes with GFR
2 episodes with GFR
3 episodes with GFR
2 episodes with GFR
GFR is back to talk Friday night lights in Sacramento! Who gave these guys a radio show The post Griz Fan Radio – Week 8 appeared first on Montana Mint - The greatest website north of Wyoming..
GFR is back to talk Friday night lights in Sacramento! Who gave these guys a radio show The post Griz Fan Radio – Week 8 appeared first on Montana Mint - The greatest website north of Wyoming..
The FiltrateJoel Topf @kidneyboy.bsky.socialSwapnil Hiremath @hswapnil.medsky.socialNayan Arora captainchloride.bsky.socialSopia Ambruso @sophia-kidney.bsky.socialSpecial Guests Brendon Neuen @brendonneuen.bsky.social Associate Professor and Program Lead, Renal and Metabolic at The George Institute for Global Health. Nephrologist and Director of Kidney Trials at Royal North Shore Hospital.Neuen has had three prior appearances on Freely Filtered: EMPA Kidney, DUPLEX and Sparsentan in FSGS, FLOW and SemaglutideMuthiah Vaduganathan @mvaduganathan on X. Cardiologist at Brigham and Women's Hospital and Harvard Medical School. Assistant Professor of Medicine.Editing byJoel TopfThe Kidney Connection written and performed by Tim YauShow NotesDONATE to NephJC! Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes NEJM | NephJC SummaryFIDELIO Bakris et al, NEJM 2020 | NephJC Summary; subgroup throws doubt on efficacy of finerenone in patients on flozinsFIGARO Pitt et al, NEJM 2021; subgroups clearly shows finerenone works, flozins or notNEJM editorial (wrongly) saying do not use Flozins unless on RASi Don't use dual RAS blockade ONTARGET Yusuf et al, NEJM 2008; VA NEPHRON-D Fried et al NEJM 2013Why we cannot study finerenone in HFrEF (RALES Pitt et al NEJM 1999) Muthu is jealous of GFR slope and albuminuria surrogate endpoints and wants to borrow them for HFpEF (Inker et al EHJ 2025)Combination therapy and CV outcomes in hypertension (Wang et al JAMA Card 2024 on low dose combinations and BP; Egan et al Blood Pressure 2022 review of topic) CONFIRMATION HF trial registry entry (Finerenone and Empagliflozin in hospitalized patients with HF)23:20: Nayan and Swap miss a chance to say ‘de-flozination' to discuss stopping a flozin which would allow a patient to be included in the trial Finerenone is a CYP3A4 substrate (Heinig et al Clin Pharmacokinetics 2023); Useful list of CYP3A4 inducers and inhibitors Everyone should get an ABPM (Bugeja et al CMAJ 2022)EASiKIDNEY study design Albuminuria mediates CKD benefits with Finerenone (Agarwal et al Ann Intern Med 2023)GFR slope and Albuminuria and the FDA (Taylor et al eClin Med 2025) Dapagliflozin and Eplerenone combination crossover trial (Provenzano et al JASN 2022)Joel gets promoted! (PBFluids reflection) Bluesky NephJC Chat discussion on ‘renal remission' Withdrawal of Finerenone and worse outcomes from FINEARTS (Vaduganathan et al JACC 2025)Combination therapies Analysis from Brendan and Muthu (Neuen et al Circulation 2024)Do not use KFRE when GFR > 60 (KDIGO Practice Point 2.2.4: Note that risk prediction equations developed for use in people with CKD G3–G5, may not be valid for use in those with CKD G1–G2) Finerenone vs Spironolactone trial in Primary Aldosteronism (Hu et al Circulation 2025)FIND CKD trial design (Heerspink et al NDT 2025) FINE-ONE trial design (Heerspink et al Diab Res Practice 2023) Tubular SecretionsNayan keeping his chin up as Yankees lose and Mariners follow (MLB Playoffs)Sophia's adventures with Beekeeping (Royal Jelly?) Brendon loves listening to ‘Susan' by Raye Muthu is back into Taekwondo Swap is still reading Martha Wells (Witch King on GoodReads)Joel will be hiking the Laugavegur trail in Iceland
GFR is back! This week Mike, Kyle, and Brint wrap up thoughts on the homecoming weekend and events and how UM marketing hit a home run. They discuss the Griz at the midway point of the season, and then scout out the Sacred Heart Pioneers The post Griz Fan Radio – Week 7 – Homecoming recap, midway point, Sacred Heart appeared first on Montana Mint - The greatest website north of Wyoming..
GFR is back! This week Mike, Kyle, and Brint wrap up thoughts on the homecoming weekend and events and how UM marketing hit a home run. They discuss the Griz at the midway point of the season, and then scout out the Sacred Heart Pioneers The post Griz Fan Radio – Week 7 – Homecoming recap, midway point, Sacred Heart appeared first on Montana Mint - The greatest website north of Wyoming..
Send us a textWelcome to Guilders-Ford Radio, a Necromunda podcast broadcasting from the East Gate Docks of Hive Primus (via Guildford Games Club, Surrey, UK).This episode of Guilders-Ford Radio lands hot on the heels of Rosco and Leigh's recent trip to Broxbourne Wargames Club's ‘Scratcher's Spill' narrative weekender.Joined by Broxbourne co-founder and returning guest of the show Adam Smith, the boys give a blow-by-blow account of the weekend's misdeeds, while Adam shares the challenges and triumphs of running your own Necromunda event.This month has seen Necromunda's hives reinforced with brand new Palanite Enforcer minatures and a fantastic new book, Bastions of Law. With precious little time with the tome ahead of recording, what do the GFR gang make of the post-Book of Judgement changes?As ever, we round up the episode with an update on our recent hobby - with Dixie literally surrounded by Prussians, and Leigh completely obsessed with the new AK-Interactive paint pens.We'd like to take the opportunity to thank all our listeners who have chosen to support us on Patreon & Buzzsprout - your contributions help us make a better show!• Flow • Denny Wright • Stefan Sahlin • Matt Miler • Matti Puh • Nick McVett •Warhammer in the Dark •From_Somewhere • Alfonso • The Traitor • Johnny DeVille • Stephan B • Jeff Nelson • Lankydiceroller • Morskul • Beau • Justin Clark • Dr.Toe • Mikael Livas • Josh Reynolds • StandStab • ChestDrain • Scott Spieker • Tucker Steel • Shaughn • Stewart Young • Goatincoat • Jason • Joseph Serrani • Billy • Phil • Stephen Griffiths • Søren D • Spruewhisperer • Kevin Fowler • Scott Spieker • Andy Tabor • TheMichaelNimmo • Tucker Steel • Dave Shearman • Shaughn • Stewart Young •Damien Davis • Wayne Jeffrey • Frawgenstein • Matthey Mulcahy • William Payne •Thomas Laycock • Stephen Livingston • Tyler Anderson • McGobbo • Jed Tearle • Gene Archibald • James Marsden • John Haynes • Ryan Taylor • Yuki van Elzelingen • Dick Linehan • Rhinoxrifter • Shawn Hall • Eric McKenzie • Paul Shaw • Jenifer • Drew Williams • Greg Miller • Andy Farrell • Nate Combrink • Don Johnson • Michael Yule • Joe Roberts • TheRedWolf • Lukasz Jainski • Aaron Vissers • One Punch Orlock (Tom) • Matt Price • ShnubutsSupport the showHelp us make better content, and download free community resources!www.patreon.com/guildersfordradioAny comments, questions or corrections? We'd love to hear from you! Join the Guilders-Ford Radio community oveSupport the showHelp us make better content, and download free community resources!www.patreon.com/guildersfordradioAny comments, questions or corrections? We'd love to hear from you! Join the Guilders-Ford Radio community over at;https://linktr.ee/guildersfordradiowww.instagram.com/guildersfordradiowww.facebook.com/guildersfordradioGuildersFordRadio@Gmail.com ** Musical Attribution - Socket Rocker by (Freesound - BaDoink) **
GFR is back! We put a final bow on the Indiana State blowout win and look ahead to the Idaho Vandals The post Griz Fan Radio – week 4, getting ready for Idaho appeared first on Montana Mint - The greatest website north of Wyoming..
GFR is back! We put a final bow on the Indiana State blowout win and look ahead to the Idaho Vandals The post Griz Fan Radio – week 4, getting ready for Idaho appeared first on Montana Mint - The greatest website north of Wyoming..
The GFR is back, this time we were on a new location and clearly need some better work in our noise reduction. We'll get better, we promise. This week's show has final thoughts from the thrilling UND game. From there we discuss what we'd like to see against Indiana State The post Griz Fan Radio – week 3, UND recap / Indiana State preview appeared first on Montana Mint - The greatest website north of Wyoming..
The GFR is back, this time we were on a new location and clearly need some better work in our noise reduction. We'll get better, we promise. This week's show has final thoughts from the thrilling UND game. From there we discuss what we'd like to see against Indiana State The post Griz Fan Radio – week 3, UND recap / Indiana State preview appeared first on Montana Mint - The greatest website north of Wyoming..
Famous last words by one of the GFP's contributors. Who, as of this recording has still not lived up to his promise. Stay tuned to the GFR this week to see if Brint comes through. In the meanwhile, we've got a hoot wine / GFP beer fueled 3 hour episode for you. This episode covers [&hellip The post Griz Fan Podcast – “If the Griz win this I'll swim in the Clark Fork” appeared first on Montana Mint - The greatest website north of Wyoming..
Famous last words by one of the GFP's contributors. Who, as of this recording has still not lived up to his promise. Stay tuned to the GFR this week to see if Brint comes through. In the meanwhile, we've got a hoot wine / GFP beer fueled 3 hour episode for you. This episode covers [&hellip The post Griz Fan Podcast – “If the Griz win this I'll swim in the Clark Fork” appeared first on Montana Mint - The greatest website north of Wyoming..
Welcome to Guilders-Ford Radio, a Necromunda podcast broadcasting from the East Gate Docks of Hive Primus (via Guildford Games Club, Surrey, UK).Summer has departed and few Necromunda previews have appeared, but GFR are back once again to discuss all things Underhive.This month we're joined by a genuine YouTube celebrity - Damon from Wellywood Wargaming! After his own successful delve into community and house rules, we thought we'd jump onto the Wellywood bandwagon and throw our two creds into the fighting pit.We reached out to you, our wonderful community, for your amendments to the current 'Munda ruleset, and you didn't disappoint. We've received a plethora of fantastic suggestions and changes, the highlights of which we discuss in-episode, as well as Dixie and Damon's own house rules.A massive thankyou to the following arbitrators for their contributions;Lee Reason (Basingstoke Necromunda)@morja477Jan Diemer (Poor Mans Haven)@myksminis@stinky_troll@jenovaprojecttabletop (Leodis Games)Mike Stuart@ShnubutsGreg Miller - (Sutton Templars Gaming Club)@adammbsmith (Broxbourne Wargames Club)Steve MonaghanStuart Hesketh@flugerhousegaming@Mcgobbo_paintsAs usual, we round out the episode with our team hobby updates, including just how little prep Rosco and Leigh have done ahead of Adam Smith's impending Scratcher's Spill event.We'd like to take the opportunity to thank all our listeners who have chosen to support us on Patreon & Buzzsprout - your contributions help us make a better show!• Flow • Denny Wright • Stefan Sahlin • Matt Miler • Matti Puh • Nick McVett •Warhammer in the Dark •From_Somewhere • Alfonso • The Traitor • Johnny DeVille • Stephan B • Jeff Nelson • Lankydiceroller • Morskul • Beau • Justin Clark • Dr.Toe • Mikael Livas • Josh Reynolds • StandStab • ChestDrain • Scott Spieker • Tucker Steel • Shaughn • Stewart Young • Goatincoat • Jason • Joseph Serrani • Billy • PhiSupport the showHelp us make better content, and download free community resources!www.patreon.com/guildersfordradioAny comments, questions or corrections? We'd love to hear from you! Join the Guilders-Ford Radio community over at;https://linktr.ee/guildersfordradiowww.instagram.com/guildersfordradiowww.facebook.com/guildersfordradioGuildersFordRadio@Gmail.com ** Musical Attribution - Socket Rocker by (Freesound - BaDoink) **
Title: One Family, Three Transplant Journeys: Life with Alport Syndrome
If you're curious as to if you have any stored emotions or trauma that might be causing your illness, preventing you from achieving your or even just showing up as the best, authentic version of yourself, I invite you to take my free Stored Emotions and Trauma Quiz How often do you think about your kidneys?In this episode, I sit down with Dr. Robin Rose, a longtime voyager and pioneer in conscious and holistic healing whose path went from nursing to nurse practitioner to medical school. Her passion for kidney health was sparked by her own experience with kidney cancer and kidney disease, and the decade-long recovery that led her to a new paradigm she calls phenology, the art and clinical science of kidney success.We talk about exactly what to look for in labs (including how to think about GFR), the emotional and spiritual energetics behind kidney dysfunction, and the top lifestyle moves to make when kidney function isn't where it should be. We also get into why kidneys are so often overlooked in medicine and how Dr. Rose rebuilt her health after a nephrectomy. You'll Learn:Labs to consider for assessing kidney healthWhat a healthy GFR level isEnergetics, emotional, and spiritual aspects underlying kidney dysfunction and diseaseTop 10 lifestyle changes for poor kidney functionThe hidden early signs of kidney decline most doctors missHow conventional and even functional medicine often overlook kidney healthKey lifestyle shifts that can improve kidney performance and energy levelsThe quiet damage high animal protein diets can cause in compromised kidneysWhat it feels like to rebuild health after losing a kidneyHow spiritual practices and mindset can influence physical healingThe overlooked role of kidney tubules and how to test their functionPractical ways to reduce kidney-toxic exposures in daily lifeTimestamps: [00:00] Introduction [05:44] Robin shares her journey through illness, surgery, and kidney cancer diagnosis [14:59] Discovering functional and regenerative approaches to improve GFR [24:53] Emotional, spiritual, and energetic aspects of kidney health [34:27] Why kidneys are often overlooked in conventional and functional medicine [42:58] Understanding kidney tubules and overlooked testing options [53:22] Diet changes that protect kidney function and common mistakes to avoid [1:02:47] Reducing toxins and environmental exposures that harm kidneys [1:12:55] Mindset, self-love, and adapting to support long-term healing [1:21:40] Key lifestyle factors for kidney regeneration and successResources Mentioned:Renology Peptides by Robin Rose | BookLearn more from Robin by checking out her websiteFind More From Dr. Stephanie Davis:Dr. Stephanie Davis | WebsiteQuantum Rx | InstagramQuantum Rx | Skool
In this episode of the Gladden Longevity Podcast, Dr. Jeffrey Gladden speaks with Dr. Robin Rose about her personal journey with kidney cancer and her insights into kidney health. They discuss the importance of understanding kidney function, the role of peptides and bioregulators in improving kidney health, and the impact of lifestyle choices on kidney function. Dr. Rose emphasizes the need for a positive mindset and proactive measures to optimize kidney health, including dietary changes and the use of specific peptides. The conversation also touches on the significance of measuring kidney function and the effects of toxins and TMAO on overall health. For Audience · Use code 'Podcast10' to get 10% OFF on any of our supplements at https://gladdenlongevityshop.com/ ! Takeaways · Dr. Robin Rose shares her personal journey with kidney cancer. · Understanding GFR is crucial for assessing kidney function. · Peptides can play a significant role in kidney health. · Bioregulator peptides help reverse kidney decline. · A positive mindset is essential for health improvement. · Lifestyle changes are necessary for kidney optimization. · Toxins in food can negatively impact kidney health. · TMAO is linked to cardiovascular risks in kidney disease. · Regular monitoring of kidney function is important. · Self-love and care are vital for health management. Chapters 00:00 Introduction to Kidney Health and Personal Journey 06:08 The Role of Lifestyle in Kidney Health 10:42 Bioregulator Peptides and Kidney Success 16:25 Innovative Strategies for Kidney Health 25:35 The Role of Peptides in Health 32:33 Kidney Function and Circadian Rhythms 39:10 Oxidative Stress and Inflammation in Kidney Health 45:00 Dietary Considerations for Kidney Health 49:33 Resources for Kidney Health and Patient Empowerment To learn more about Robin: Email: rosegardenmedicine@gmail.com Website: renologyiskidneysuccess.com Reach out to us at: Website: https://gladdenlongevity.com/ Facebook: https://www.facebook.com/Gladdenlongevity/ Instagram: https://www.instagram.com/gladdenlongevity/?hl=en LinkedIn: https://www.linkedin.com/company/gladdenlongevity YouTube: https://www.youtube.com/channel/UC5_q8nexY4K5ilgFnKm7naw
Welcome to Guilders-Ford Radio, a Necromunda podcast broadcasting from the East Gate Docks of Hive Primus (via Guildford Games Club, Surrey, UK).After a recording hiatus, GFR are back to our regularly scheduled programming. This month, we dive into Deepfort - Dixie's latest narrative campaign that saw three weeks of simultaneous multiplayer games spread across two battlefields. Did the guilder caravan make it to the embattled Precinct 19 outpost? Did the Ash Waste Nomads succeed in breaking through the entrenched defenders to plunder the spoils within? All will be revealed this episode!Recent Necromunda news from Warhammer has seen some fantastic Palanite Enforcer models and a new book previewed - hear the team's hot takes on the forthcoming reinforcements.As usual, we round out the episode with our hobby updates and discussion, including forthcoming community events, shiny new loot courtesy of Sump Lab, and Rosco's imminent departure back to his native Westcountry, and his newly adopted FLGS, Entoyment in Poole.We'd like to take the opportunity to thank all our listeners who have chosen to support us on Patreon & Buzzsprout. Your contributions help us make a better show! • Flow • Denny Wright • Stefan Sahlin • Matt Miler • Matti Puh • Nick McVett •Warhammer in the Dark •From_Somewhere • Alfonso • The Traitor • Johnny DeVille • Stephan B • Jeff Nelson • Lankydiceroller • Morskul • Beau • Justin Clark • Dr.Toe • Mikael Livas • Josh Reynolds • StandStab • ChestDrain • Scott Spieker • Tucker Steel • Shaughn • Stewart Young • Goatincoat • Jason • Joseph Serrani • Billy • Phil • Stephen Griffiths • Søren D • Spruewhisperer • Kevin Fowler • Scott Spieker • Andy Tabor • TheMichaelNimmo • Tucker Steel • Dave Shearman • Shaughn • Stewart Young •Damien Davis • Wayne Jeffrey • Frawgenstein • Matthey Mulcahy • William Payne •Thomas Laycock • Stephen Livingston • Tyler Anderson • McGobbo • Jed Tearle • Gene Archibald • James Marsden • John Haynes • Ryan Taylor • Yuki van Elzelingen • Dick Linehan • Rhinoxrifter • Shawn Hall • Eric McKenzie • Paul Shaw • Jenifer • Drew Williams • Greg Miller • Andy Farrell • Nate Combrink • Don Johnson • Michael Yule • Joe Roberts • TheRedWolf • Lukasz Jainski • Aaron Vissers • One Punch Orlock (Tom) • Matt Price • ShnubutsSupport the showHelp us make better content, and download free community resources!www.patreon.com/guildersfordradioAny comments, questions or corrections? We'd love to hear from you! Join the Guilders-Ford Radio community over at;https://linktr.ee/guildersfordradiowww.instagram.com/guildersfordradiowww.facebook.com/guildersfordradioGuildersFordRadio@Gmail.com ** Musical Attribution - Socket Rocker by (Freesound - BaDoink) **
Did you know that people who have received a kidney transplant are at a much higher risk for skin cancer? We sat down with experts to discuss how you can lower your risk. In this episode we heard from: Dr. Cerrene Giordano is a dermatologist and Mohs Micrographic surgeon at Roswell Park Comprehensive Cancer Center in Buffalo, New York. She specializes in treating skin cancers, particularly in patients who are high risk such as those who have received organ transplants, have weakened immune systems, or a genetic predisposition to skin cancer development. Her expertise includes skin cancer surgery, wound reconstruction, and the management of skin cancers such as melanoma, basal cell carcinoma, and squamous cell carcinoma, to name a few. Dr. Giordano is also involved in research aimed at improving pain management following dermatologic surgeries and exploring advanced imaging techniques to enhance surgical outcomes. Kent Bressler is a retired RN who was diagnosed with FSGS in 1984, and received a living donor transplant from his brother Kip in 1987. Kent is an active advocate for preemptive kidney transplant and has on the recommendation of NKF worked closely with the DoD and PCORI as a consumer peer reviewer. He is an NKF peer mentor and advocate who has collaborated on an editorial “Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of Chronic Kidney Disease,” published in AJKD in 2019. He will also be participating in the development of the new NKF Patient Network serving on the Data Input and Integration Committee. He has been an active hill advocate for the NKF for six years and was the proud recipient of the 2017 Richard K. Salick Advocacy Award. Kent is also an Army Veteran and retired from the Veterans administration as an RN. He is the co-founder of Kidney Solutions a not for profit program in Texas that assists patients and families in the transplant process and in finding a donor. He is currently an assistant team leader for Region 7. Kent and Cathy Bressler have been married for 56 years and their family consists of Gretchen and Todd Rossington and their son Colt and Celeste and Alex Brown and their children John Banks, Catherine and Alexis Brown. Risa Simon is a passionate author, speaker, mentor, kidney patient coach and advocate. As the founder and CEO of The Proactive Path and the TransplantFirst Academy, her mission is to help all kidney disease patients advocate for their best life possible—the life she now lives. As a preemptive kidney transplant recipient, Risa was able to circumvent the need for dialysis. This is her hope for all eligible kidney patients. Risa gives back a good portion of her time by serving on various advisory committees, such as the National Kidney Foundation's (NKF's) Kidney Action committee, the American Association of Kidney Patients (AAKP) program and convention committees and she chairs the Phoenix Chapter's Polycystic Kidney Disease (PKD) education committee. She is also a member of the PKD Legacy Society and serves as a Peer Mentor for the National Kidney Foundation (NKF). Risa's message is all about empowering kidney patients to bring their voice to life. Additional Resources: Dr. Cerrene Giordano Protect the Skin You're In Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.
Most people believe kidney decline is a one-way street to dialysis. But what if that's simply not true? In this episode of ReInvent Healthcare, Dr. Ritamarie is joined by Dr. Robin Rose, a pioneering physician who turned her own diagnosis of kidney cancer and stage four kidney disease into a journey of recovery—and a new medical paradigm called Renology. Discover what functional medicine gets wrong about kidneys and how practitioners can spot the early signs of decline before it's too late.What You'll Discover Inside:The Hidden Kidney Crisis: Why conventional medicine often misses the earliest signs of declineRenology Defined: A new, functional lens for understanding and healing kidney diseasePeptides & Kidney Repair: How bioregulators work, and why they're not a magic bulletThe Lab Markers That Matter: Functional ranges for GFR, phosphorus, cystatin C, and moreThe Kidney's Web of Influence: Why supporting the kidneys improves brain, thyroid, and cardiovascular healthRobin's Personal Healing Journey: A deep dive into her personal tools for reversing her diseaseResources and Links:Download the transcript hereDownload our FREE Metabolic Health Guide here.Join the Next-Level Health Practitioner Facebook group here for free resources and community support.Visit INEMethod.com for advanced health practitioner training and tools to elevate your clinical skills and grow your practice by getting life-changing results.Check out other podcast episodes here.Dr Robin's Resources:Website: RenologyIsKidneySuccess.comBook: Renology Peptides by Dr. Robin RoseAbout Dr. Robin Rose:Robin Rose MD has been a world traveler, a health food chef, journalist, professional dancer, and artist. After some years of collecting life experiences, she went to nursing school then became a family nurse practitioner while learning nutrition, herbal medicine, acupuncture, massage, homeopathy. Then she made the leap and went to university of Arizona college of medicine and then completed a family medicine residency- while continuing to study holistic and functional medicine. She practiced for many years in southern Oregon offering a holistic array of loveliness and healing medical guidance. After a series of intense stresses she found herself challenged with kidney cancer and severe kidney disease. In the past decade she has become agile in the realm of kidney regeneration and has created a new paradigm of kidney success - ways to engage nature and mind body spirit to achieve the innate healing that leads to thriving. Her recent book RENOLOGY Peptides is a text that dives into the root to succeed - using bioregulator peptides as a way to illuminate the path.
Bumper summer show coming up today with special guests Johnny Van Zant and Rickey Medlocke from Lynyrd Skynyrd talk about the new live release recorded at the Ryman Auditorium Nashville on what turned out to be the final live show of founding member Gary Rossington who sadly passed away just months after this recording.John Coghlan is the original drummer from Status Quo and the frantic four drummer joins me to look back to the very first live release from Quo in 77 the shows were recorded in Glasgow in October of 76 and these have just been released as a super deluxe edition with all three shows remastered and we talk about 50 years of "On The Level"And getting us underway today Mark Farner of Grand Funk Railroad looks back to this weekend back in 1969 when they opened the first mega festival it was "Atlanta Pop Festival" GFR opened the show that day and it went down so well they were invited back to play again on a later slot.
In this Thursday's 12 Minute Talk, Wade checks in with an update on the Geissele GFR. He breaks down the group sizes and range data using various 6mm ARC loads. Whether you're running a similar setup or just curious how the GFR is stacking up, this one's for you.Let us know in the comments what you're running in your GFR.#Geissele #GFR #AR15 #TexasPredatorHunting #PredatorHunting #RifleSetupListen to the Podcast:Texas Predator Hunting Podcast:
Our guest today is Reverend Kenn Blanchard. Kenn was once known internationally as the Black Man With A Gun. Before Google and Facebook existed, he played a monumental role in laying the groundwork for national concealed carry, the Heller Decision, and HR 218, the Law Enforcement Officers Safety Act. Today, he is a musician and caregiver for his wife. He has a new book called Finding Joy in the Blues available on Amazon. 1) You were our very first guest on GFR, and much has happened in the past ten years since we first met. But, one thing hasn't changed, and that is that you have been Serving others your entire life. From your time in the Military, law enforcement, 2A Advocacy, and now your wife in her time of health needs. What drives you to show up in all of these roles? 2) Your wife is still recovering from a brain tumor. Your retirement years have not worked out the way you planned. Yet, you write a book about joy. Tell us about that. 3) One of the chapters in your book is called “A Preacher and a Rabbi”. In a time when some are trying to sew division based on every conceivable metric – race, class, religion, political ideology, etc – you two found an amazing connection and friendship. What was your common bond? 4) Where does 2A Advocacy fit in your life nowadays? 5) Having already planned for a future that didn't quite work out, how do you now make plans for what is next? 6) How do people follow you and buy your books? Originally Aired 5.16.25
View the Show Notes For This Episode Dr. Robin Rose discusses Kidney Care with Peptides with Dr. Ben Weitz. [If you enjoy this podcast, please give us a rating and review on Apple Podcasts, so more people will find The Rational Wellness Podcast. Also check out the video version on my WeitzChiro YouTube page.] Podcast Highlights In this episode of the Rational Wellness Podcast, Dr. Ben Weitz hosts Dr. Robin Rose to discuss crucial insights into kidney health. They explore the kidney's functions, including filtering blood, regulating electrolytes, and converting vitamin D. The conversation delves into chronic kidney disease, highlighting that symptoms can arise even in stage two when GFR drops below 60. Dr. Rose emphasizes the importance of early detection and intervention, discussing concepts such as uremic dysbiosis, endothelial damage, leaky gut, and the impact of toxins. They also touch on natural and supplemental approaches to support kidney health, like using bio-regulator peptides, nutritional therapy, and plant-based diets. Additionally, Dr. Rose shares her personal experience with kidney cancer and the insights she gained during her journey to recovery. 00:26 Understanding Kidney Functions and Chronic Kidney Disease 02:10 In-Depth Discussion with Dr. Robin Rose 02:34 The Complexities of Kidney Health 04:28 Kidney and Gut Health Connection 04:54 Challenges in Measuring Kidney Function 08:48 Managing Kidney Health Through Diet and Lifestyle 28:43 Nutritional Supplements for Kidney Health 33:23 Butyrate and Gut Health 33:56 Cardiovascular Markers and Genomics 34:59 Kidney Health Botanicals 37:31 Peptides and Their Benefits 43:06 Bio-Regulator Peptides 51:31 Personal Kidney Health Journey 52:48 Hydration and Herbal Teas 54:40 Final Thoughts and Resources ________________________________________________________________________________________________________ Dr. Robin Rose is a Medical Doctor and an expert at supporting kidney health using a wholistic approach and peptides. She has recently published a book, Renology Peptides: Kidney Success with Bioregulator Peptides. Renology Peptides is a comprehensive clinical volume that presents an evidence-guided scholarly tool to deepen understanding of regenerative kidney medicine and bioregulator peptides. Her website is Renology is Kidney Success. Dr. Ben Weitz is available for Functional Nutrition consultations specializing in Functional Gastrointestinal Disorders like IBS/SIBO and Reflux and also Cardiometabolic Risk Factors like elevated lipids, high blood sugar, and high blood pressure. Dr. Weitz has also successfully helped many patients with managing their weight and improving their athletic performance, as well as sports chiropractic work by calling his Santa Monica office 310-395-3111.
Howie and Harlan are joined by Joel Bervell, a recent medical school graduate who uses social media platforms to combat misinformation and explain racial biases in healthcare. Harlan discusses his new Wall Street Journal commentary highlighting the link between viral infections and chronic diseases; Howie reports on powerful new evidence for the effectiveness of the HPV vaccine and warns of the dangers of a vaccine-skeptical presidential administration. Links: Viral Infection and Chronic Disease Harlan Krumholz: “How to Lead a Chronic Disease Revolution” “A natural experiment on the effect of herpes zoster vaccination on dementia” “Unexplained post-acute infection syndromes” Joel Bervell Joel Bervell Joel Bervell on TikTok Joel Bervell on Instagram “TikTok's 'Medical Mythbuster' Helps Save Lives By Tackling Racial & Gender Disparities In Healthcare” “How the pulse oximeter became infamous on TikTok” “Racial Bias in Pulse Oximetry Measurement” Joel Bervell's TikTok on the pulse oximeter Joel Bervell: “The eGFR Equation” “Race Correction and the X-Ray Machine: The Controversy over Increased Radiation Doses for Black Americans in 1968” Joel Bervell: “For over 50 years, X-ray technicians were taught to administer higher radiation doses to Black patients” Joel Bervell's Instagram reel on bias in the measurement of lung capacity Made to Stick: Why Some Ideas Survive and Others Die Joel Bervell on LinkedIn Joel Bervell on YouTube: The Doctor Is In Kickstarter: The Doctor Is In “Medical mythbuster Joel Bervell, MD, on how to teach kids about medicine and address misinformation” Cleveland Clinic: Amyloidosis Joel Bervel's Instagram reel on the GFR equation “Abandoning a Race-biased Tool for Kidney Diagnosis” “OPTN Board approves elimination of race-based calculation for transplant candidate listing” “America's News Influencers” “85th Annual Peabody Awards Announce Nominees for the Arts, Children's/Youth, Entertainment, and Interactive & Immersive Categories Vaccines and the Federal Healthcare Agencies Health & Veritas Episode 165: “Aging in Bursts and Other News” “U.S. government researchers present ‘phenomenal' new data on HPV vaccines” “Invasive cervical cancer incidence following bivalent human papillomavirus vaccination: a population-based observational study of age at immunization, dose, and deprivation” “Kennedy played key role in Gardasil vaccine case against Merck” “RFK Jr. suggests some vaccines are risky or ineffective, downplays measles threat” “FDA chief says they're looking at whether to approve COVID shots for next winter” “How Marty Makary's FDA is embracing a more skeptical view of vaccines” Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.
Today, we're diving into one of the most misunderstood, wrongly demonized, and yet most important pieces of your nutrition strategy: PROTEIN.We're going deep into:Why so many people still believe protein is dangerous — especially for your kidneysWhere these outdated beliefs came fromThe role of protein in muscle gain, fat loss, aging, and long-term healthWhy the RDA is setting you up for failureWhat YOU can do today to get the benefits of a high-protein lifestyleResources:1. High-Protein Diets and Kidney Function in Healthy Adults:Study: A Systematic Review of Renal Health in Healthy Individuals Consuming High Protein DietsFindings: This review analyzed multiple randomized controlled trials and found that increased protein intake led to higher glomerular filtration rates (GFR), all within normal kidney function ranges. The data suggest that higher protein consumption does not adversely affect kidney health in healthy adults. Study: Effect of a High-Protein Diet on Kidney Function in Healthy Adults: Results from the OmniHeart TrialFindings: This study concluded that a healthy diet rich in protein increased estimated GFR. However, it noted that the long-term effects of high-protein diets on kidney health remain uncertain.2. Protein Intake and Sarcopenia (Muscle Loss) in Older Adults:Study: Protein Intake and Sarcopenia in Older Adults: A Systematic Review and Meta-AnalysisFindings: The meta-analysis indicated that older adults with sarcopenia consumed significantly less protein than their non-sarcopenic peers, suggesting that inadequate protein intake may be associated with muscle loss in the elderly. Study: Role of Dietary Protein in the Sarcopenia of AgingFindings: The study suggests that moderately increasing daily protein intake beyond 0.8 g/kg/day may enhance muscle protein anabolism, potentially mitigating age-related muscle loss. Protein & Kidney Health in Healthy IndividualsSystematic Review: High Protein Diets & Renal FunctionConclusion: No negative effects on kidney function in healthy adults.
Thank you for joining us for our 2nd Cabral HouseCall of the weekend! I'm looking forward to sharing with you some of our community's questions that have come in over the past few weeks… Anne: Listen to your podcast everyday and I learned so many helpful health tips. Thank you. I have recently developed dry mouth at night while I'm sleeping. I drink a lot of water during the day and I have not started any new medication. What is the cause of dry mouth and what natural remedies would you suggest. Thank you Fred: Hi Dr Cabral My name is fred and have been listening to you for the last year I truly believe your are in this t help . I have recently purchased the vitamin. And heavy metal detox tests for my wife and myself I am 63 years old and unfortunately had h pylori and was on antibiotics for 2 weeks about 2 months ago I not sure the impact but it has seemed to have worked My concern is that I have a eGFR of 46 I have an enlarged liver I am a non drinker and starting to eat better I went off my statin and am on blood pressure medication I do not sleep well at all Hoping to afford to do the big 5 one day I am Canadian and our dollar is very bad What can I do to save my kidneys naturally Kristin: I've heard that Ashwaganda supplements are not good for those with Hashimotos. Is this accurate? I've also read and experienced so many benefits from it. Mandy: High creatinine level question. Hi, I greatly appreciate all the wonderful info that you and your team provide to those of us that want to live our best and healthy life!m Is there a causal relationship between menopause and an increase in creatinine? Recently had my labs done and my creatinine was 1.24, BUN 19, and GFR 54. Any advice and recommendations to bring my level down would be greatly appreciated. I'm an active 49 yr old. Thank you for your help. Mandy Mandy: Hi! Do you recommend mattress vacuums (specifically Jigoo, Jimmy, or Ranvoo)?Also, we just heard about the Apollo 2nd Generation Do you recommend it? Thank you for tuning into this weekend's Cabral HouseCalls and be sure to check back tomorrow for our Mindset & Motivation Monday show to get your week started off right! - - - Show Notes and Resources: StephenCabral.com/3292 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!
N Engl J Med 2006;355:2395-407Am Heart J 2011;161:611-21Background: Registry data suggests that 10-20% of patients with a STEMI present more than 12 hours after the onset of symptoms. The optimal treatment for such patients is unknown. In some cases, the inciting event may have occurred weeks prior and been mistaken for indigestion or another non-life threatening condition. Such patients may present to the hospital with a new diagnosis of congestive heart failure or atrial fibrillation. Echocardiography often reveals a a large wall motion abnormality, perfusion testing demonstrates an infarct with peri-infarct ischemia and an occluded vessel is seen on angiography. Should we try to open it? On the one hand, the damage has been done. Attempting to open an occluded vessel is associated with higher procedural risks and the patient's themselves are more often than not sub-optimal candidates for intervention; often having some combination of heart failure, LV dysfunction, older age, multimorbidity and hemodynamic instability. But on the other hand, revascularization restores blood flow and that has to count for something, right?The Occluded Artery Trial (OAT) tested the hypothesis that a strategy of routine PCI for total occlusion of the infarct-related artery 3 to 28 days after AMI would improve cardiac outcomes compared to medical therapy alone.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber.Patients: Patients were eligible if coronary angiography, performed 3 to 28 days after MI, showed a total occlusion of the infarct-related artery with poor antegrade flow and either an EF less than 50% or the occlusion was in the proximal portion of a major coronary vessel with a large risk region, or both. The qualifying period of 3 to 28 days was based on calendar days with day 1 being the onset of symptoms and thus, the minimal time from the AMI to angiography was just over 24 hours. [This is important, readers should not take the inclusion criteria of 3 to 28 days to mean that patients were not eligible if angiography was performed 2.5 mg/dl, left main or 3 vessel disease, angina at rest, and severe ischemia on stress testing (stress testing was required if the infarct zone was not akinetic or dyskinetic).Baseline characteristics: The trial included 2,166 patients - 1,082 randomized to PCI and 1,084 to medical therapy. The average age of patients was 59 years and 78% were men. Over 80% were white. The median time between AMI and randomization was 8 days. Patients had normal kidney function with an average GFR of 81 ml/min. The mean EF was 48% with 20% of patients having an EF
Podcast Overview The podcast, hosted by Valentin Fuster on January 21, 2025, provides an in-depth review of the FINEARTS-HF trial, which evaluated the efficacy of the non-steroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). The episode highlights findings published in the Journal of the American College of Cardiology (JACC). Introduction to the FINEARTS-HF Trial (00:03:19 – 00:05:56) The FINEARTS-HF trial demonstrated that finerenone reduced heart failure events by 16% compared to placebo in patients with HFmrEF/HFpEF. However, cardiovascular death rates were similar between groups, making the overall clinical impact moderate. Finerenone's Impact on Quality of Life (00:05:59 – 00:12:46) The trial assessed quality of life using the Kansas City Cardiomyopathy Questionnaire (KCCQ), revealing only a slight improvement (1.62 points) with finerenone. Critics, including the FDA, questioned the clinical relevance of these results and suggested the need for simpler, more meaningful patient-reported outcome measures. Finerenone in Patients with Recent Worsening Heart Failure (00:12:58 – 00:20:30) Patients with recent worsening heart failure showed a greater absolute benefit from finerenone, as they were at higher risk of recurrent events and cardiovascular death. However, further studies are needed to confirm these findings. Finerenone's Role in Obese Patients with HFmrEF/HFpEF (00:20:31 – 00:25:20) In obese patients, the benefits of finerenone were consistent across body mass index (BMI) categories, with a possible greater effect in those with higher BMI. Nevertheless, the reliance on BMI as a metric for obesity was criticized, and alternative measures were recommended. Finerenone and Kidney Outcomes (00:25:23 – 00:40:52) Finerenone showed a modest reduction in albuminuria but did not significantly alter kidney disease progression. Initial declines in glomerular filtration rate (GFR) were noted but should not automatically lead to discontinuation of therapy. Mixed findings highlight the need for more research to understand its renal effects. Conclusion (00:40:54 – 00:44:05) The FINEARTS-HF trial was recognized as a landmark study, showcasing modest benefits of finerenone in a challenging patient population. The podcast calls for continued research to refine quality of life metrics, better understand obesity's role in HFmrEF/HFpEF, and explore finerenone's long-term renal and cardiovascular impacts.
Podcast Overview The podcast, hosted by Valentin Fuster on January 21, 2025, provides an in-depth review of the FINEARTS-HF trial, which evaluated the efficacy of the non-steroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). The episode highlights findings published in the Journal of the American College of Cardiology (JACC). Introduction to the FINEARTS-HF Trial (00:03:19 – 00:05:56) The FINEARTS-HF trial demonstrated that finerenone reduced heart failure events by 16% compared to placebo in patients with HFmrEF/HFpEF. However, cardiovascular death rates were similar between groups, making the overall clinical impact moderate. Finerenone's Impact on Quality of Life (00:05:59 – 00:12:46) The trial assessed quality of life using the Kansas City Cardiomyopathy Questionnaire (KCCQ), revealing only a slight improvement (1.62 points) with finerenone. Critics, including the FDA, questioned the clinical relevance of these results and suggested the need for simpler, more meaningful patient-reported outcome measures. Finerenone in Patients with Recent Worsening Heart Failure (00:12:58 – 00:20:30) Patients with recent worsening heart failure showed a greater absolute benefit from finerenone, as they were at higher risk of recurrent events and cardiovascular death. However, further studies are needed to confirm these findings. Finerenone's Role in Obese Patients with HFmrEF/HFpEF (00:20:31 – 00:25:20) In obese patients, the benefits of finerenone were consistent across body mass index (BMI) categories, with a possible greater effect in those with higher BMI. Nevertheless, the reliance on BMI as a metric for obesity was criticized, and alternative measures were recommended. Finerenone and Kidney Outcomes (00:25:23 – 00:40:52) Finerenone showed a modest reduction in albuminuria but did not significantly alter kidney disease progression. Initial declines in glomerular filtration rate (GFR) were noted but should not automatically lead to discontinuation of therapy. Mixed findings highlight the need for more research to understand its renal effects. Conclusion (00:40:54 – 00:44:05) The FINEARTS-HF trial was recognized as a landmark study, showcasing modest benefits of finerenone in a challenging patient population. The podcast calls for continued research to refine quality of life metrics, better understand obesity's role in HFmrEF/HFpEF, and explore finerenone's long-term renal and cardiovascular impacts.
Podcast Overview The podcast, hosted by Valentin Fuster on January 21, 2025, provides an in-depth review of the FINEARTS-HF trial, which evaluated the efficacy of the non-steroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). The episode highlights findings published in the Journal of the American College of Cardiology (JACC). Introduction to the FINEARTS-HF Trial (00:03:19 – 00:05:56) The FINEARTS-HF trial demonstrated that finerenone reduced heart failure events by 16% compared to placebo in patients with HFmrEF/HFpEF. However, cardiovascular death rates were similar between groups, making the overall clinical impact moderate. Finerenone's Impact on Quality of Life (00:05:59 – 00:12:46) The trial assessed quality of life using the Kansas City Cardiomyopathy Questionnaire (KCCQ), revealing only a slight improvement (1.62 points) with finerenone. Critics, including the FDA, questioned the clinical relevance of these results and suggested the need for simpler, more meaningful patient-reported outcome measures. Finerenone in Patients with Recent Worsening Heart Failure (00:12:58 – 00:20:30) Patients with recent worsening heart failure showed a greater absolute benefit from finerenone, as they were at higher risk of recurrent events and cardiovascular death. However, further studies are needed to confirm these findings. Finerenone's Role in Obese Patients with HFmrEF/HFpEF (00:20:31 – 00:25:20) In obese patients, the benefits of finerenone were consistent across body mass index (BMI) categories, with a possible greater effect in those with higher BMI. Nevertheless, the reliance on BMI as a metric for obesity was criticized, and alternative measures were recommended. Finerenone and Kidney Outcomes (00:25:23 – 00:40:52) Finerenone showed a modest reduction in albuminuria but did not significantly alter kidney disease progression. Initial declines in glomerular filtration rate (GFR) were noted but should not automatically lead to discontinuation of therapy. Mixed findings highlight the need for more research to understand its renal effects. Conclusion (00:40:54 – 00:44:05) The FINEARTS-HF trial was recognized as a landmark study, showcasing modest benefits of finerenone in a challenging patient population. The podcast calls for continued research to refine quality of life metrics, better understand obesity's role in HFmrEF/HFpEF, and explore finerenone's long-term renal and cardiovascular impacts.
Podcast Overview The podcast, hosted by Valentin Fuster on January 21, 2025, provides an in-depth review of the FINEARTS-HF trial, which evaluated the efficacy of the non-steroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). The episode highlights findings published in the Journal of the American College of Cardiology (JACC). Introduction to the FINEARTS-HF Trial (00:03:19 – 00:05:56) The FINEARTS-HF trial demonstrated that finerenone reduced heart failure events by 16% compared to placebo in patients with HFmrEF/HFpEF. However, cardiovascular death rates were similar between groups, making the overall clinical impact moderate. Finerenone's Impact on Quality of Life (00:05:59 – 00:12:46) The trial assessed quality of life using the Kansas City Cardiomyopathy Questionnaire (KCCQ), revealing only a slight improvement (1.62 points) with finerenone. Critics, including the FDA, questioned the clinical relevance of these results and suggested the need for simpler, more meaningful patient-reported outcome measures. Finerenone in Patients with Recent Worsening Heart Failure (00:12:58 – 00:20:30) Patients with recent worsening heart failure showed a greater absolute benefit from finerenone, as they were at higher risk of recurrent events and cardiovascular death. However, further studies are needed to confirm these findings. Finerenone's Role in Obese Patients with HFmrEF/HFpEF (00:20:31 – 00:25:20) In obese patients, the benefits of finerenone were consistent across body mass index (BMI) categories, with a possible greater effect in those with higher BMI. Nevertheless, the reliance on BMI as a metric for obesity was criticized, and alternative measures were recommended. Finerenone and Kidney Outcomes (00:25:23 – 00:40:52) Finerenone showed a modest reduction in albuminuria but did not significantly alter kidney disease progression. Initial declines in glomerular filtration rate (GFR) were noted but should not automatically lead to discontinuation of therapy. Mixed findings highlight the need for more research to understand its renal effects. Conclusion (00:40:54 – 00:44:05) The FINEARTS-HF trial was recognized as a landmark study, showcasing modest benefits of finerenone in a challenging patient population. The podcast calls for continued research to refine quality of life metrics, better understand obesity's role in HFmrEF/HFpEF, and explore finerenone's long-term renal and cardiovascular impacts.
Podcast Overview The podcast, hosted by Valentin Fuster on January 21, 2025, provides an in-depth review of the FINEARTS-HF trial, which evaluated the efficacy of the non-steroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). The episode highlights findings published in the Journal of the American College of Cardiology (JACC). Introduction to the FINEARTS-HF Trial (00:03:19 – 00:05:56) The FINEARTS-HF trial demonstrated that finerenone reduced heart failure events by 16% compared to placebo in patients with HFmrEF/HFpEF. However, cardiovascular death rates were similar between groups, making the overall clinical impact moderate. Finerenone's Impact on Quality of Life (00:05:59 – 00:12:46) The trial assessed quality of life using the Kansas City Cardiomyopathy Questionnaire (KCCQ), revealing only a slight improvement (1.62 points) with finerenone. Critics, including the FDA, questioned the clinical relevance of these results and suggested the need for simpler, more meaningful patient-reported outcome measures. Finerenone in Patients with Recent Worsening Heart Failure (00:12:58 – 00:20:30) Patients with recent worsening heart failure showed a greater absolute benefit from finerenone, as they were at higher risk of recurrent events and cardiovascular death. However, further studies are needed to confirm these findings. Finerenone's Role in Obese Patients with HFmrEF/HFpEF (00:20:31 – 00:25:20) In obese patients, the benefits of finerenone were consistent across body mass index (BMI) categories, with a possible greater effect in those with higher BMI. Nevertheless, the reliance on BMI as a metric for obesity was criticized, and alternative measures were recommended. Finerenone and Kidney Outcomes (00:25:23 – 00:40:52) Finerenone showed a modest reduction in albuminuria but did not significantly alter kidney disease progression. Initial declines in glomerular filtration rate (GFR) were noted but should not automatically lead to discontinuation of therapy. Mixed findings highlight the need for more research to understand its renal effects. Conclusion (00:40:54 – 00:44:05) The FINEARTS-HF trial was recognized as a landmark study, showcasing modest benefits of finerenone in a challenging patient population. The podcast calls for continued research to refine quality of life metrics, better understand obesity's role in HFmrEF/HFpEF, and explore finerenone's long-term renal and cardiovascular impacts.
Podcast Overview The podcast, hosted by Valentin Fuster on January 21, 2025, provides an in-depth review of the FINEARTS-HF trial, which evaluated the efficacy of the non-steroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). The episode highlights findings published in the Journal of the American College of Cardiology (JACC). Introduction to the FINEARTS-HF Trial (00:03:19 – 00:05:56) The FINEARTS-HF trial demonstrated that finerenone reduced heart failure events by 16% compared to placebo in patients with HFmrEF/HFpEF. However, cardiovascular death rates were similar between groups, making the overall clinical impact moderate. Finerenone's Impact on Quality of Life (00:05:59 – 00:12:46) The trial assessed quality of life using the Kansas City Cardiomyopathy Questionnaire (KCCQ), revealing only a slight improvement (1.62 points) with finerenone. Critics, including the FDA, questioned the clinical relevance of these results and suggested the need for simpler, more meaningful patient-reported outcome measures. Finerenone in Patients with Recent Worsening Heart Failure (00:12:58 – 00:20:30) Patients with recent worsening heart failure showed a greater absolute benefit from finerenone, as they were at higher risk of recurrent events and cardiovascular death. However, further studies are needed to confirm these findings. Finerenone's Role in Obese Patients with HFmrEF/HFpEF (00:20:31 – 00:25:20) In obese patients, the benefits of finerenone were consistent across body mass index (BMI) categories, with a possible greater effect in those with higher BMI. Nevertheless, the reliance on BMI as a metric for obesity was criticized, and alternative measures were recommended. Finerenone and Kidney Outcomes (00:25:23 – 00:40:52) Finerenone showed a modest reduction in albuminuria but did not significantly alter kidney disease progression. Initial declines in glomerular filtration rate (GFR) were noted but should not automatically lead to discontinuation of therapy. Mixed findings highlight the need for more research to understand its renal effects. Conclusion (00:40:54 – 00:44:05) The FINEARTS-HF trial was recognized as a landmark study, showcasing modest benefits of finerenone in a challenging patient population. The podcast calls for continued research to refine quality of life metrics, better understand obesity's role in HFmrEF/HFpEF, and explore finerenone's long-term renal and cardiovascular impacts.
Podcast Overview The podcast, hosted by Valentin Fuster on January 21, 2025, provides an in-depth review of the FINEARTS-HF trial, which evaluated the efficacy of the non-steroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). The episode highlights findings published in the Journal of the American College of Cardiology (JACC). Introduction to the FINEARTS-HF Trial (00:03:19 – 00:05:56) The FINEARTS-HF trial demonstrated that finerenone reduced heart failure events by 16% compared to placebo in patients with HFmrEF/HFpEF. However, cardiovascular death rates were similar between groups, making the overall clinical impact moderate. Finerenone's Impact on Quality of Life (00:05:59 – 00:12:46) The trial assessed quality of life using the Kansas City Cardiomyopathy Questionnaire (KCCQ), revealing only a slight improvement (1.62 points) with finerenone. Critics, including the FDA, questioned the clinical relevance of these results and suggested the need for simpler, more meaningful patient-reported outcome measures. Finerenone in Patients with Recent Worsening Heart Failure (00:12:58 – 00:20:30) Patients with recent worsening heart failure showed a greater absolute benefit from finerenone, as they were at higher risk of recurrent events and cardiovascular death. However, further studies are needed to confirm these findings. Finerenone's Role in Obese Patients with HFmrEF/HFpEF (00:20:31 – 00:25:20) In obese patients, the benefits of finerenone were consistent across body mass index (BMI) categories, with a possible greater effect in those with higher BMI. Nevertheless, the reliance on BMI as a metric for obesity was criticized, and alternative measures were recommended. Finerenone and Kidney Outcomes (00:25:23 – 00:40:52) Finerenone showed a modest reduction in albuminuria but did not significantly alter kidney disease progression. Initial declines in glomerular filtration rate (GFR) were noted but should not automatically lead to discontinuation of therapy. Mixed findings highlight the need for more research to understand its renal effects. Conclusion (00:40:54 – 00:44:05) The FINEARTS-HF trial was recognized as a landmark study, showcasing modest benefits of finerenone in a challenging patient population. The podcast calls for continued research to refine quality of life metrics, better understand obesity's role in HFmrEF/HFpEF, and explore finerenone's long-term renal and cardiovascular impacts.
Send us a textFacing a life-altering health crisis, Pesh discovered he was living with just one underdeveloped kidney, a revelation that propelled him into a new chapter as a patient advocate. In this episode, join the SCM nurses as Pesh Patel shares his remarkable journey through the challenges of kidney disease, including emergency blood transfusions and a failed kidney transplant. Pesh shares the customized approach he's taken with his healthcare team and the significant role his diet plays in managing his condition. His inspiring story emphasizes the empowering potential of personal advocacy and nutrition in chronic health management.Listeners will gain valuable insights into the transformative power of taking charge of one's health journey. Drawing from personal experience, Pesh delves into the importance of early detection and proactive kidney health management. Our conversation turns to the promising role of data analytics and AI in identifying undiagnosed cases, and the critical need for understanding health metrics like creatinine and GFR. We also delve into the emotional and cognitive challenges of dialysis, highlighting the significance of self-care for both patients and their loved ones.The episode moves beyond personal stories to explore broader themes, including the potential benefits of the Keto diet for kidney health, particularly for those with polycystic kidney disease. We navigate the complex terrain of balancing diet and health, reflecting on the challenges of maintaining an alkaline diet and sourcing healthy fats. As we discuss plans to broaden our advocacy efforts through interactive content, the importance of education and collaboration shines through, offering listeners a comprehensive look at managing and advocating for kidney health.
The FiltrateJoel TopfSwapnil HiremathAC GomezJordy CohenNayan AroraSpecial Guest Brendon NuenEditing bySimon Topf and Nayan AroraShow NotesFINEARTS-HF in NEJM FINEARTS Kidney outcomes in JACCFINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes in Nature Medicine discussion in NephJC BARACH-D: Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial (Nature Medicine)Live Freely Filtered at KidneyWkSwapnil comes out as a SpiroStan post to NephJC TOPCATTOPCAT primary publication TOPCAT North American results TOPCAT funny business explained AHA/ACC/HFSA Heart Failure Guidelines (PDF)SGLT2i are 2aMRA are a 2bARBs are a 2bARNI are a 2bClinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to SpironolactoneKansas city cardiomyopathy questionnaire in patients with CKD without a diagnosis of heart failure: https://pubmed.ncbi.nlm.nih.gov/21187260/GFR slope with steroidal MRAs in HF: https://onlinelibrary.wiley.com/doi/10.1002/ejhf.2635Why Has it Been Challenging to Modify Kidney Disease Progression in Patients With Heart Failure? (JACC)Tubular SecretionsSwap: Disclaimer on Apple TVAC: Duo Lingo Plushy (Amazon)Nayan: The Puzzle BoxJordy: Project Hail MaryBrendon has a podcast, The Kidney Compass with Shikha Wadhwani. And he recommends singer-songwriter, Maggie Rogers (YouTube)Joel: The Singularity Is Nearer: When We Merge with AI by Ray KurzweilClosing music, Tim Yau with The Kidney Connection
“The nurse's role in monitoring the lab values really depends on the clinics you're working at, but really when our patients are receiving treatment, especially in the infusion center, the nurses should be looking at those lab values prior to treatment being started,” Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, clinical nurse specialist at Karmanos Cancer Center in Michigan told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS during a conversation about how to monitor and educate patients with cancer. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn [#] contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by November 29, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: The learner will report an increase in knowledge related to monitoring labs and educating patients with cancer. Episode Notes Complete this evaluation for free NCPD. Oncology Nursing Podcast™ episodes: Episode 319: Difficult Conversations About Pregnancy Testing in Cancer Care Episode 311: Standardized Pregnancy Testing Processes in Cancer Care Episode 183: How Oncology Nurses Find and Use Credible Patient Education Resources Episode 179: Learn How to Educate Patients During Immunotherapy Episode 87: What Are the Biggest Barriers to Patient Education? Episode 43: Sharing Patient, Provider, and Caregiver Resources ONS Voice articles: Patient Education Reduces Barriers and Increases Adherence Rates Nurses Must Understand Health Disparities to Provide Effective Patient Education Oncology Nurses Can Improve Oral Medication Management With Patient Education Program ONS Course: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ Oncology Nursing Forum article: Antineoplastic Therapy Administration Safety Standards for Adult and Pediatric Oncology: ASCO-ONS Standards Clinical Calculations—ANC Huddle Card To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an Oncology Nursing Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. “Your traditional chemotherapy agents are the ones that we see the most lab abnormalities with, and we can predict those a little bit more with the advent of more of the advanced targeted therapies and immunotherapies, we still see lab values that are altered because of the way that the treatment works, but they may differ a little bit than what we traditionally saw with our normal chemotherapy agents.” TS 2:51 “I talked about the lifespan of all the other cells, and Neutrophils are usually what stop treatment, and part of that is, is that the lifespan of a neutrophil is 48 hours. It is proliferated very frequently in the bone marrow. But that is usually what we see. The cells that we see that stop treatment, and as you mentioned earlier, classic chemotherapy really the types of treatment that historically, we've been given and we have given to patients, and we've seen those blood counts really significantly impacted.” TS 6:21 “Kidney function, or renal function tests, are really determined whether the kidneys are functioning the way they should be. We look at an estimated glomerular filtration rate, or GFR, which is really based on the patient's protein level, their age, gender, and race. And the test really looks at how efficiently the kidneys are clearing the waste from the body. So that's really one that we need to look at, especially as we're giving agents that are excreted through the kidneys.” TS 12:23 “I think it's important for nurses to start looking at lab results with their patient very early on, you know, even before treatment starts, so they understand what the normals look like. So when they do get those lab results, because now pretty much everybody has patient portals, right? So the labs are reported in there, and they're seeing the labs before they're talking to their providers. if we can start early on and talk to them about what the normal lab values are, what they mean, and what we're looking at when we're drawing these labs. I think it's really important for the patient.” TS 27:00
SummaryJazrome Coulter shared his journey as a stand-up comedian, highlighting his battle with kidney disease and the impact of his difficult childhood on his personal growth. He emphasized the importance of choosing to grow from grief after the death of his twin brother in 2018 and his mission to educate others about kidney disease. Additionally, he discussed the significance of his kidney transplant and encouraged people to consider becoming organ donors.Key PointsJazrome Coulter shares his journey as a stand-up comedian, revealing that he has been dealing with kidney disease for almost a decade and expressing gratitude for the experience despite its challenges. 5:06Jazrome Coulter discusses his difficult childhood, including his mother's struggles with addiction, being shuffled between family members, and the impact of these experiences on his life choices and personal growth. 6:00Jazrome Coulter reflects on the death of his twin brother in 2018 as a turning point in his life, emphasizing the choice to grow from grief rather than be broken by it. 21:00Jazrome Coulter concludes by expressing his mission to educate others about kidney disease and inspire hope, emphasizing that every day presents a choice for individuals facing challenges. 26:31Jazrome Coulter shares his journey of self-discovery through comedy, detailing how he processed grief after his brother's death and the impact it had on his life. 40:22Sam Knickerbocker prompts Jazrome Coulter to discuss his experience with kidney failure and how it relates to his past health issues, including performance problems and back pain. 48:22Jazrome Coulter explains the significance of his kidney transplant and how his GFR levels have improved over two years, indicating a strong match with the donor. 1:06:38Jazrome Coulter provides information on various organizations for kidney donations and encourages people to consider becoming organ donors. 1:08:36
The show opens with Adam talking to Jason “Mayhem” Miller about once again getting flipped off on the freeway, the glorious end to Mike August's “Brisket Quest”, and AOC & Tim Walz's reaction to Tony Hinchcliffe's appearance at a Donald Trump rally. Next, comedian Bret Ernst returns to the show to talk about his new special, Uncaged. They also discuss how songs about being in a band tend to be good, while songs about evil women are always bad. Then, Jason “Mayhem” Miller reads the news including stories about how Burlington, Vermont leadership is now calling for more officers after admitting that defunding the police was a mistake, towns setting an age limit on trick-or-treaters, and Philadelphia's D.A. suing Elon Musk to stop his million dollar giveaway. Finally, Mark Farner from Grand Funk Railroad joins the show to talk about his new solo album, why GFR isn't in the Rock & Roll Hall of Fame, what it's like hearing covers of his songs, opening for Led Zeppelin, his songwriting process, and the potential of a GFR reunion. For more with Bret Ernst: ● NEW SPECIAL: Pete Davidson Presents: Bret Ernst Uncaged - available on YouTube ● INSTAGRAM: @breternst ● TIKTOK: @breternst ● WEBSITE: bretcomedy.com For more with Mark Farner: ● NEW SOLO ALBUM: Closer to My Home - available November 8th ● INSTAGRAM: @farner_nine ● TWITTER/X: @farner_nine ● WEBSITE: markfarner.com Thank you for supporting our sponsors: ● http://SimpliSafe.com/Adam ● BotanicTonics.com, use code ADAM ● QualiaLife.com/Adam ● http://Sendthevote.org/Adam or text ADAM to 33022 ● http://OReillyAuto.com/Adam
Imagine a treatment that not only helps manage diabetes but also holds the potential to reverse kidney failure — what was once thought to be impossible. The recent FLOW study has remarkable groundbreaking evidence that GLP-1 receptor agonists can significantly improve kidney function in chronic kidney disease (CKD) patients. And while researchers try to understand the full implications of these findings, one thing is clear: the landscape of kidney disease treatment may never be the same again. In this podcast, we'll dive into the results of the FLOW trial and explore what they may mean for people at risk for kidney failure. What are GLP-1 Agonists? GLP-1 (glucagon-like peptide-1) agonists are a class of drugs that mimic the effects of the natural hormone GLP-1. They enhance insulin secretion, inhibit glucagon release, and slow gastric emptying, improving blood sugar control. Beyond their primary use in diabetes management, GLP-1 agonists have been studied for various conditions, including obesity and cardiovascular disease prevention. The Study Overview The FLOW trial, which stands for "Fasting and Long-acting GLP-1 Receptor Agonist in Patients with Chronic Kidney Disease," focused on the impact of GLP-1 receptor agonists, specifically semaglutide, on patients with chronic kidney disease (CKD) and type 2 diabetes (those most at risk for kidney failure). Researchers observed a remarkable trend: patients receiving semaglutide demonstrated stabilization of kidney function and signs of renal recovery. This was groundbreaking, as reversing kidney damage has long been considered a near-impossible feat. Study Objectives The primary goal was to determine whether treatment with GLP-1 receptor agonists could improve kidney outcomes in patients with CKD. Study Design Participants: The study enrolled >3500 adults with type 2 diabetes and CKD. Intervention: Participants were randomized to receive either semaglutide or a placebo. Primary Outcomes: The main outcomes included changes in glomerular filtration rate (GFR) and the incidence of major adverse kidney events (kidney failure- need for transplantation or dialysis). Key Findings Renal Function Improvement: Patients on semaglutide showed significant improvements in glomerular filtration rates (GFR), a key indicator of kidney function. Reduced Inflammation: The drugs appeared to lower levels of inflammatory markers associated with kidney damage, suggesting a protective effect. Metabolic Benefits: Improvements in blood sugar control and weight loss were also observed, contributing to overall health and potentially alleviating stress on the kidneys. Adverse Events: The treatment was generally well-tolerated, with a favorable safety profile. Ethical Considerations As the results began to emerge, the ethical landscape of the study shifted dramatically. The control group, which was not receiving semaglutide, was found to be at a significantly higher risk of kidney deterioration. With compelling evidence that the GLP-1 agonist was safe and potentially life-saving, the ethics committee determined withholding treatment from any participants was no longer justifiable. Consequently, the study was halted prematurely to allow all participants access to the medication, prioritizing patient welfare over the continuation of research under an inequitable framework. This decision underscores the ethical responsibility of researchers to ensure that all patients receive the best possible care, especially when clear benefits are identified. Implications for Future Research While the early termination of the study raises questions about the completeness of the data collected, it also opens new avenues for further research. The findings encourage more extensive clinical trials to explore the mechanisms behind the renal protective effects of GLP-1 agonists. Additionally, there is a growing interest in investigating these drugs' long-term effects on kidney health and their potential role in preventing disease progression. As further studies unfold, there is hope that GLP-1 agonists will become a standard part of kidney disease management, potentially transforming outcomes for millions affected by this condition. Thanks again for listening to The Peptide Podcast. We love having you as part of our community. If you love this podcast, please share it with your friends and family on social media, and have a happy, healthy week! We're huge advocates of elevating your health game with nutrition, supplements, and vitamins. Whether it's a daily boost or targeted support, we trust and use Momentous products to supercharge our wellness journey. Momentous only uses the highest-quality ingredients, and every single product is rigorously tested by independent third parties to ensure their products deliver on their promise to bring you the best supplements on the market.
DISCOUNT CODES BELOW! Welcome to Episode 64 with 3D Ground force reaction specialist Steve Furlonger. We discussed the development in technology, common issues with players GFRs, using drills that specifically target improving a players GFRs. Steve is often hosting educational seminars fro coaches to help develop their knowledge in GFR's for more information be sure to follow him on his Instagram page below. Information on my online coaching programs: https://skillest.com/app/profile/toby-mcgeachie Interested in being a partner of Podcast? Email me at toby@tmgolf.com.auWATCH THE PODCAST ON YOUTUBE: https://www.youtube.com/@TMGOLFMAJOR SPONSOR SKILLEST:STUDENTS: Download the https://skillest.com/ and use code TOBYM to get 20% off your first lesson package with any coach!COACHES: Use code TOBYM to get your first 2 months free https://skillest.com/PUTTING SEGMENT SPONSOR:BACK 2 BASICS - Putting Mirror accessories included use Code TM15 for 15% https://tinyurl.com/Back2Basics-DiscountTRAIN AT HOME SPONSOR:Net Return Australia - #1 Net trusted by Bryson DeChambeau use Code TMGOLF for 10% off https://www.tmgolf.com.au/the-net-return/FIND Steve on IG: https://www.instagram.com/sfgolfperform/?hl=enTOBY'S SOCIALS: Instagram: https://www.instagram.com/tmgolf_/ instagram: https://www.instagram.com/thegolfcoachpodcast/?hl=en Facebook: https://www.facebook.com/TMGolfCoach/ Linkedin: https://www.linkedin.com/in/toby-mcgeachie-7a74488a/ Youtube: https://www.youtube.com/c/TMGOLF Take Care,
A 77-year-old man is in for a routine follow up visit. He has its twenty-year history of type 2 diabetes and hypertension as well as a 5-year history of stage 3B chronic kidney disease, or CKB. At this visit, his A1C is 8.4% and his estimated GFR is 42 mL per minute. His BP is 128/76. He states he's feeling well and denies headache, visual changes, dizziness and hypoglycemic episodes. His medications include metformin, amlodipine, lisinopril and rosuvastatin. In reviewing his current medication, the NP considers which of the following options?A. Prescribe glipizideB. Add pioglitazone C. Continue on his current medication without adjustment D. Initiate therapy with Canagliflozin---YouTube: https://www.youtube.com/watch?v=rOuR7ATNdMQ&list=PLf0PFEPBXfq592b5zCthlxSNIEM-H-EtD&index=92Visit fhea.com to learn more!
Listener Q: "What is the difference between eGFR and GFR? Is one better than the other for getting tested for PKD, or should I ask for both? I am worried I am not getting the labs I need to stay informed about my kidneys." Answer: Tune in and find out: What GFR is What eGFR is If there are the same What you need to know about each and if you need to get both tested for Polycystic Kidneys MASTER YOUR LABS FOR PKD Yes, Sign Me Up! Learn More - https://www.thepkddietitian.com/masteryourlabs RESOURCES Episode #33 What is Cystatin C and Should You Get it Tested? https://www.thepkddietitian.com/podcasts/the-pkd-dietitian-podcast/episodes/2148345282 NKF's eGFR Calculator https://www.kidney.org/professionals/gfr_calculator LET'S CONNECT INSTAGRAM: https://www.instagram.com/the.pkd.dietitian/ FACEBOOK: https://www.facebook.com/PKDdietitian EMAIL: https://www.thepkddietitian.com/site/contact DISCLAIMER The PKD Dietitian Podcast is meant for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider with any medical questions or concerns.
In this episode, we follow the remarkable story of a 72-year-old man who was on the verge of starting dialysis due to advanced stage 4 kidney disease. Faced with a grim prognosis, he embraced an unconventional treatment plan involving daily sauna sessions, a diet of boiled foods, and rigorous lifestyle changes. Over time, his kidney function dramatically improved, with his GFR rising from 21 to 54, and his overall health transformed. The episode explores the science behind his recovery and offers practical tips for supporting kidney health through diet, exercise, and holistic therapies.
Legendary career singer/songwriter Mark Farner of Mark Farner's American Band returns with “Closer To My Home” celebrating the 55th anniversary of the classic song “(I'm Your Captain) Closer To My Home” made famous by Grand Funk Railroad plus “Anymore”, “The Prisoner”, “Same Game”, “Façade”, the bonus track “Friends Forever” and more! Mark also gives us an update on the last release “From Chile with Love” where $3 for every DVD goes towards Veteran's Transitional Housing Services plus the stories behind the music and how GFR sold over 30M worldwide with 16 gold & platinum albums and selling out faster than the Beatles at Shea Stadium still a record to this day! Check out the amazing Mark Farner and his latest release coming Friday, Nov. 8th on many major platforms and www.markfarner.com ! #markfarner #markfarnersamericanband #GFR #grandfunkrailroad #closertomyhome #55thanniversary #imyourcaptain #anymore #theprisoner #samegame #facade #friendsforever #fromchilewithlove #spreaker #iheartradio #spotify #applemusic #youtube #anchorfm #bitchute #rumble #mikewagner #themikewagnershow #mikewagnermarkfarner #themikewagnershowmarkfarner --- Support this podcast: https://podcasters.spotify.com/pod/show/themikewagnershow/support
Legendary career singer/songwriter Mark Farner of Mark Farner's American Band returns with “Closer To My Home” celebrating the 55th anniversary of the classic song “(I'm Your Captain) Closer To My Home” made famous by Grand Funk Railroad plus “Anymore”, “The Prisoner”, “Same Game”, “Façade”, the bonus track “Friends Forever” and more! Mark also gives us an update on the last release “From Chile with Love” where $3 for every DVD goes towards Veteran's Transitional Housing Services plus the stories behind the music and how GFR sold over 30M worldwide with 16 gold & platinum albums and selling out faster than the Beatles at Shea Stadium still a record to this day! Check out the amazing Mark Farner and his latest release coming Friday, Nov. 8th on many major platforms and www.markfarner.com ! #markfarner #markfarnersamericanband #GFR #grandfunkrailroad #closertomyhome #55thanniversary #imyourcaptain #anymore #theprisoner #samegame #facade #friendsforever #fromchilewithlove #spreaker #iheartradio #spotify #applemusic #youtube #anchorfm #bitchute #rumble #mikewagner #themikewagnershow #mikewagnermarkfarner #themikewagnershowmarkfarner --- Support this podcast: https://podcasters.spotify.com/pod/show/themikewagnershow/support
Welcome to Guilders-Ford Radio, a Necromunda podcast broadcasting from the East Gate Docks of Hive Primus (via Guildford Games Club, Surrey, UK).In Episode 24 - ‘Warp Portal or Body Shop', after many months of anticipation, the GFR team have finally play-tested the Spyrers - and are ready to share the Spire-born sociopath's strengths, weaknesses and counters.The Necromunda community continue to submit their queries to our High Arbitrator, and the latest installment of #DearDixie sees James and the gang do their best to field *your* burning rules and background questions.In the final segment of the episode, take malicious joy in listening to Rosco and Leigh's panic with the imminent arrival of SumpCon 2024 - where we discover they've done next to nothing in terms of preparation.We'd like to take the opportunity to thank all our listeners who have chosen to support us on Patreon & Buzzsprout. Your contributions help us make a better show! • Jason • Joseph Serrani • Billy • Phil • Stephen Griffiths • Søren D • Spruewhisperer • Kevin Fowler • Scott Spieker • Andy Tabor • TheMichaelNimmo • Tucker Steel • Dave Shearman • Shaughn • Stewart Young •Damien Davis • Wayne Jeffrey • Frawgenstein • Matthey Mulcahy • William Payne •Thomas Laycock • Stephen Livingston • Tyler Anderson • McGobbo • Jed Tearle • Gene Archibald • James Marsden • John Haynes • Ryan Taylor • Yuki van Elzelingen • Dick Linehan • Rhinoxrifter • Shawn Hall • Eric McKenzie • Paul Shaw • Jenifer • Drew Williams • Greg Miller • Andy Farrell • Nate Combrink • Don Johnson • Michael Yule • Joe Roberts • TheRedWolf • Lukasz Jainski • Aaron Vissers • One Punch Orlock (Tom) • Matt Price • Shnubuts • Christopher Næss • Rob Harrison • Colm Kiely • Dave • Grant • Stephen Briley • Szymon Brzozowski • Angus Lee • Mykola Romaniuk • Jason Turner • Janner558 • Christian Jansch • Joe Reynolds • Xavier Lamrecht • Matt R • Andrew Gomes • Iain Torrance • Mark Southerd • Ben • James Dix • Eddie Turner Support the showHelp us make better content, and download free community resources!www.patreon.com/guildersfordradioAny comments, questions or corrections? We'd love to hear from you! Join the Guilders-Ford Radio community over at;https://linktr.ee/guildersfordradiowww.instagram.com/guildersfordradiowww.facebook.com/guildersfordradioGuildersFordRadio@Gmail.com ** Musical Attribution - Socket Rocker by (Freesound - BaDoink) **
The draft order:Sophia AmbrusoNayan AroraSwapnil HiremathAC GomezJoel TopfEditor Nayan AroraShow NotesPrevious drafts:2021 KDIGO Hypertension —Joel, Sophia, Swap, Nayan, Josh2021 ASN Kidney Week Draft—Joel, Sophia, Swap, Nayan, Jennie2022 The ISPD Peritonitis Guideline— Joel, Sophia, Swap, Nayan2022 ASN Kidney Week Draft—Joel, Sophia, Swap, Nayan2023 ASN Kidney Week Draft—Joel, Sophia, Swap, Nayan, AC, Josh2024 KDIGO CKD Clinical Practice Guideline —Joel, Sophia, Swap, Nayan, Josh, ACThe guidelineThe NephJC discussion Part 1 | Part 2First RoundSophia's Pick 3.7.1 We recommend treating patients with type 2 diabetes (T2D), CKD, and an eGFR ≥20 ml/min per 1.73 m2 with an SGLT2i (1A).Not Nayan's Pick 3.7.3: We suggest treating adults with eGFR 20 to 45 ml/min per 1.73 m2 with urine ACR
CardioNerds (Drs. Gurleen Kaur and Richard Ferraro) and episode FIT Lead Dr. Saahil Jumkhawala (Cardiology Fellow at the University of Miami) discuss SGLT inhibitors, focusing on the biology of SGLT and its inhibition, with Dr. Katherine Tuttle (Executive Director for Research at Providence Healthcare, Co-Principal Investigator of the Institute of Translational Health Sciences, and Professor of Medicine at the University of Washington). Show notes were drafted by Dr. Saahil Jumkhawala. The episode audio was engineered by CardioNerds intern Christiana Dangas. This episode was produced in collaboration with the American Society of Preventive Cardiology (ASPC) with independent medical education grant support from Lexicon Pharmaceuticals. CardioNerds Prevention PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls - The Biology of SGLT Inhibition with Dr. Katherine Tuttle SGLT inhibitors, while initially developed as antidiabetic medications, have been shown to be beneficial for cardiovascular and renal outcomes. These benefits result from their on-target glucosuric effects and additional off-target effects. The side effect profiles of SGLTis are primarily mediated by glucose reabsorption in their target tissues. The side effect profile of SGLTis must be considered when prescribing these medications and is generally favorable for SGLT2is versus SGLT1is. Once SGLTis are prescribed, patients should be given specific attention to their eGFR, serum potassium, and clinical evaluations of volume status and blood pressure. Strategies to increase implementation of and reduce clinical inertia for these important class of medication remain an area of active investigation Show notes - The Biology of SGLT Inhibition with Dr. Katherine Tuttle What should prompt consideration of starting an SGLT inhibitor? Considerations for SGLT inhibitor initiation are based on a history of heart failure, kidney disease, and diabetes status. In the EMPA-KIDNEY trial, empagliflozin improved cardiovascular and kidney outcomes in those with low GFR (regardless of level of albuminuria). What is the mechanism of action of SGLT2 inhibitors? SGLT2 inhibitors improve glycemic control by blocking SGLT2 receptor-mediated reabsorption of glucose in the proximal convoluted tubule, where 80-90% of this reuptake occurs, and increased downstream excretion of glucose and sodium chloride. SGLT2 inhibitors provide only a modest glucose-lowering effect, particularly for patients with GFR
Welcome back to our weekend Cabral HouseCall shows! This is where we answer our community's wellness, weight loss, and anti-aging questions to help people get back on track! Check out today's questions: Taran: Hi Dr. Cabral! You are amazing and I truly appreciate your willingness to share your knowledge with the world. I was diagnosed with ichthyosis vulgaris when I was born. I have had very dry skin since birth. It was a lot worse when I was younger. It is much better, however would still be classified as very dry for a normal person. I have to regularly apply moisturizers on my entire body at least 2x daily. Thanks to your recommendation , I discovered my moisturizer was toxic (7 on ewg skin deep) I have 2 questions: 1. Can I do anything from the inside to heal my skin in the long run rather than relying on moisturizers? 2. What is the best for applying topically on skin? Oils? Moisturizers? Aleisha: Hi Dr Cabral, thank you so much for everything you do and your generosity and energy in this world. I know you don't like to discuss specific brands on the podcast however I was wondering what your thoughts are on the ‘recovery' formula from the ‘Osmosis Skincare' Wellneas range. It says it can rebuild the fat pads lost with aging, I am 33 however due to a pretty intense health journey I have lost much of the volume in my fat pads and feel I look as if have aged dramatically and am considering giving this a go. The main basis of it is that it contains omegas 3,6,7 &9 from sea buckthorn fruit, oil & pulp and some macadamia oil. It is a very expensive product and the claim is that it takes 3 bottles to see changes and 7 bottles for best results. Is there an alternative to this you recommend? Anouk: Hi there, Thanks for all the information you give out so generously. in July I tested pos. for ( ureaplasma, gardnerella, and candida alb) I took one round of doxy 7 days and a few months later I caught strep and re-tested for everything I still had the Urea +candida but I took clarithromycin for the strep. Of course all of these antibiotics were screwing up my vaginal microbiome.. I since have had a pap that came back HPV pos. ( LSIL) not sure if it the the stress of all of this but for the past few weeks i've had unbearable lower tailbone butt bone / pelvic floor aching and leg cramping, I can feel my vaginal muscles are almost in a permanent kegel and it's very hard to relax down there. Regardless of the pain i'd really like to do what I can to eradicate ALL of these things! Glenn: What is the difference between caffeine and caffeine anhydrous as found in pre workout drinks and how bad is thus compound for the body. I've found info online on preworkouts and energy drinks but they all seem to revolve around the sugars/ artificial sweeteners in them rather than the other compounds. I enjoy taking these daily and found one that's pretty clean and devoid of sugars so are these really that bad long term? Thank you Noel: What is you opinion on cupping therapy? I am not talking about wet cupping but just regular cupping. I am a 67 year old female and like 50 lbs overweight so probably have metabolic syndrome so may be prone to heart issues, stroke. But I am most concerned about my kidneys. A few years back I was diagnosed with kidney failure, GFR was 11! Now it is over 60 for the last several years. I understand if there is toxic removal it would get removed through my kidneys ( and liver) and don't want to overtax my kidneys. I am very active otherwise and don't have any aches and pain anywhere. Would also love to minimize my cellulite. Thank you for tuning into today's Cabral HouseCall and be sure to check back tomorrow where we answer more of our community's questions! - - - Show Notes and Resources: StephenCabral.com/2899 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!
© 2020-2025 Ivy Podcast Discovery LLC
